INTRODUCTION
Pediatric cancer is the number one cause of diseaserelated death in children, and brain tumors are the most common pediatric solid tumor (Udaka and Packer 2018) .
Medulloblastoma is an embryonic cerebellar tumor comprised of at least four biologically and clinically distinct molecular subgroups (Northcott et al. 2012) . One subgroup, Sonic Hedgehog (SHH)-medulloblastoma, arises through genetic alterations resulting in activation of the SHH signaling pathway, including mutations in the SHH receptor gene PTCH1, activating mutations in the transmembrane protein-coding gene Smoothened (SMO), mutations in the negative regulator gene SUFU, or amplification of the transcription factor genes GLI2 or MYCN (Johnson et al. 1996; Hahn et al. 1996; Goodrich et al. 1997; Kenney et al. 2003; Ayrault et al. 2010; Kool et al. 2014) .
While constitutive activation of SHH signaling is required for SHH-medulloblastoma formation, studies in mice have demonstrated that additional genetic hits are required for the malignant transformation of cerebellar granule neuron progenitors (GNPs) in Ptch1 heterozygous animals (Tamayo-Orrego and Charron 2019; Oliver et al. 2005; Kessler et al. 2009; Tamayo-Orrego et al. 2016 ). Depending on the nature of these mutations, the molecular and cellular properties of the tumor may Medulloblastoma is a childhood brain tumor arising from the developing cerebellum. In Sonic Hedgehog (SHH)subgroup medulloblastoma, aberrant activation of SHH signaling causes increased proliferation of granule neuron progenitors (GNPs) and predisposes these cells to tumorigenesis. A second, cooperating genetic hit is often required to push these hyperplastic cells to malignancy and confer mutation-specific characteristics associated with oncogenic signaling. Somatic loss-of-function mutations of the transcriptional co-repressor BCOR are recurrent and highly enriched in SHH-medulloblastoma. To investigate BCOR as a putative tumor suppressor, we used a germline genetically engineered mouse model to delete exons 9/10 of Bcor (Bcor ΔE9-10 ) in GNPs during development. This leads to reduced expression of C-terminally truncated BCOR (BCOR ΔE9-10 ). While Bcor ΔE9-10 alone did not promote tumorigenesis or affect GNP differentiation, Bcor ΔE9-10 combined with loss of the SHHreceptor gene Ptch1 resulted in highly penetrant medulloblastomas. In Ptch1+/-;Bcor ΔE9-10 tumors, the growth factor gene Igf2 was aberrantly upregulated, and ectopic Igf2 overexpression was sufficient to drive tumorigenesis in Ptch1+/-GNPs. BCOR directly regulates Igf2, likely through the PRC1.1 complex; the repressive histone mark H2AK119Ub is decreased at the Igf2 promoter in Ptch1+/-;Bcor ΔE9-10 tumors. Overall, our data suggests that BCOR-PRC1.1 disruption leads to Igf2 overexpression, which transforms preneoplastic cells to malignant tumors.
change (Vogelstein and Kinzler 1993) . More importantly, understanding how these cooperating mutations contribute to malignancy may reveal new therapeutic opportunities for affected patients.
We and others previously identified recurrent inactivating mutations and insertions/deletions (indels) targeting the transcriptional co-repressor gene BCOR in SHH-medulloblastoma (Jones et al. 2012; Pugh et al. 2012; Robinson et al. 2012; Kool et al. 2014; Northcott et al. 2017 ), but the mechanism(s) underlying BCOR-associated medulloblastoma remain unclear. BCOR aberrations are implicated in a variety of pediatric cancers, including acute myeloid leukemia, retinoblastoma, sarcomas, glioblastomas, and CNS high-grade neuroepithelial tumor with BCOR alteration (CNS-HGNET-BCOR) (Mackay et al. 2017; Astolfi et al. 2015; Sturm et al. 2016; Kooi et al. 2016; Grossmann et al. 2011; Santiago et al. 2017) .
Altogether, deregulation of BCOR is implicated in at least 18 different tumor histotypes of pediatric cancer (Astolfi et al. 2019) , demonstrating the urgency in understanding BCOR function in both normal and tumorigenic cells.
BCOR was originally identified based on its interaction with the zinc finger transcription factor BCL6 and subsequently shown to be a component of a non-canonical Polycomb Repressive Complex (PRC1.1) (Huynh et al. 2000; Gearhart et al. 2006; Cao et al. 2016; Gao et al. 2012) . BCL6 can recruit BCOR to DNA via the BCL6-interacting motif found in the N-terminal half of BCOR ( Fig. 1A) (Ghetu et al. 2008 ). The C-terminus contains non-ankyrin repeats, ankyrin repeats, and the PUFD domain, which binds the Polycomb group protein PCGF1 ( Fig. 1A) (Junco et al. 2013) . These regions and their interacting partners are conserved in BCOR in mice (Wamstad and Bardwell 2007; Huynh et al. 2000; Wamstad et al. 2008 ).
BCL6 has been previously implicated in cerebellar development in mice (Tiberi et al. 2014) . Overexpression of human BCL6 suppresses medulloblastoma formation in vivo in mice, perhaps through interaction with BCOR at Gli1/Gli2 promoters (Tiberi et al. 2014 ), although Kutscher, Okonechnikov, Batora et al. recurrent BCL6 mutations have not yet been identified in SHH-medulloblastoma patient samples. While the interaction between BCOR and BCL6 may be one mode of BCOR-mediated tumor suppression, BCOR mutations seen in SHH-medulloblastoma frequently truncate the C-terminal PUFD domain ( Fig. 1A) (Northcott et al. 2017 ).
This truncation may lead to an inability to recruit PCGF1, which together with RING1B ubiquitinates histone H2A at lysine 119 (H2AK119Ub) to repress transcription of target genes Gearhart et al. 2006; Aranda et al. 2015) . Therefore, we set out to determine whether BCOR function within the PRC1.1 complex is involved in tumor suppression in SHH-medulloblastoma.
Here we show that genetic ablation of exons 9 and 10 of Bcor (Bcor ΔE9-10 ) in developing GNPs does not disrupt granule neuron differentiation in mice. Instead, Bcor ΔE9-10 cooperates with inactivation of Ptch1 to potentiate aggressive medulloblastoma formation.
BCOR occupies the Igf2 promoter region in Ptch1+/tumors, and chromatin occupancy is greatly reduced in Ptch1+/-;Bcor ΔE9-10 tumors. This reduction leads to aberrant upregulation of Igf2 in these tumors to drive tumorigenesis. Additionally, BCOR ΔE9-10 no longer binds RING1B, the catalytic subunit of the PRC1.1 complex, which leads to a global reduction of the repressive histone mark H2AK119Ub, and a reduction of this mark specifically at the Igf2 promoter, compared to Ptch1+/tumors. Our work demonstrates that loss of the C-terminus of BCOR disrupts PRC1.1 complex function to drive SHH-medulloblastoma formation.
RESULTS

BCOR is recurrently co-mutated with members of the SHH pathway in pediatric SHH-medulloblastoma
We and others previously identified BCOR as recurrently mutated or deleted in ~10% of pediatric SHH-medulloblastomas (Jones et al. 2012; Pugh et al. 2012; Robinson et al. 2012; Kool et al. 2014; Northcott et al. 2017) . We mapped the identified mutations to the BCOR coding sequence ( Fig. 1A) and determined that and tumorigenesis.
Bcor is expressed in proliferating granule neuron progenitors (GNPs) in mice
We first determined whether Bcor is normally expressed in developing cerebellar GNPs in mice, the cellof-origin for SHH-medulloblastoma (Yang et al. 2008; Schüller et al. 2008; Hovestadt et al. 2019; Vladoiu et al. 2019 ). Using RNA in situ hybridization (ISH), we found that Bcor is expressed in the outer external granule layer the C-terminal PUFD domain is inferred to be absent because of the introduction of premature STOP codons in 6/7 cases (Table 1 ). In the majority of cases (6/7), BCOR is co-mutated with members of the SHH pathway, including PTCH1 (4/6), GLI2 (1/6), SMO (1/6) or SUFU (1/6). BCOR is an X-linked gene, and the majority of affected patients were male (6/7). Given its potential as a cooperating mutation in SHH-medulloblastoma formation, we investigated the functional relevance of these mutations during normal cerebellar development Figure S1 . of the P7 cerebellum ( Fig. 1B ), similar to actively cycling cells (Ccnd2, Fig. 1C ). After cerebellar development is complete, however, Bcor is no longer expressed (P28, Fig. 1D ).
In mice heterozygous for the SHH receptor gene Ptch1
(written as Ptch1+/-hereafter), preneoplastic lesions form in 85% of mice by P21, but the majority regress by P42 Kessler et al. 2009 ). We found that
Bcor is expressed in these preneoplastic lesions but not in adjacent normal tissue ( Fig. 1E ).
To validate the in vivo expression pattern, we examined The mutations we identified in human tumors suggest the C-terminal domain of BCOR may be important for its tumor suppressive function (Fig. 1A) . To investigate the functional relevance of these mutations during GNP development and tumorigenesis, we used germline genetically engineered mouse strains to generate Cre inducible excision of Bcor exons 9 and 10 in Atoh1positive GNPs (Bcor ΔE9-10 , Fig. 1G , see Methods for details (Tara et al. 2018) ). At the protein level, this excision results in reduced expression of a truncated BCOR protein ( Fig. 1H ).
BCOR and its N-terminal interaction with BCL6 have been implicated in SHH-medulloblastoma (Tiberi et al. 2014) . We sought to determine whether BCL6-related functions were disrupted in our mouse model. First, to investigate whether BCOR ΔE9-10 interacts with BCL6, we overexpressed HA-tagged full-length BCOR or HAtagged BCOR ΔE9-10 with BCL6 in HEK293T cells and performed co-immunoprecipitation studies with the bulk protein extract. We found that BCOR ΔE9-10 interacts with BCL6 in vitro (Supplemental Fig. S1A ), suggesting that the BCL6 interacting motif is still functional. cerebellum are largely unaffected in our mouse model. We found no differences between wild-type and Bcor ΔE9-10 animals in the total number of GNP cells at P7 (PAX6positive, Supplemental To further confirm that BCL6-dependent roles of BCOR are unaffected in Bcor ΔE9-10 GNPs, we examined expression of known BCL6/BCOR-regulated genes (Tiberi et al. 2014 ). Loss of Bcl6 in cerebellar cells resulted in an increase in Gli1 and Gli2 expression, and both BCOR and BCL6 were bound at these promoter regions (Tiberi et al. 2014) . To determine whether BCOR ΔE9-10 affects expression of these and other SHH-pathway related genes in GNPs, we isolated total RNA from wild-type and Bcor ΔE9-10 GNPs and evaluated target gene expression using qPCR. In contrast to Bcl6 loss (Tiberi et al. 2014 ), loss of the region encoding the C-terminal domain of BCOR does not activate SHH signaling in P7 GNPs, including expression of Gli1, Gli2, Ccnd1, Ptch1, or Mycn (Supplemental Fig. S1S ), suggesting that BCOR ΔE9-10 does not influence BCL6-related SHH signaling repression in GNPs. Taken together, our Bcor ΔE9-10 mouse model should allow us to assess the role of BCOR, and in particular the involvement of the C-terminus and PRC1.1, in medulloblastoma formation.
Bcor ΔE9-10 significantly reduces latency and increases penetrance of Ptch1-associated medulloblastoma
Next, we examined how Bcor ΔE9-10 affects tumor formation in conjunction with Ptch1 inactivation. Of note, deletion of the region encoding the C-terminal domain of BCOR in GNPs by itself does not promote medulloblastoma ( Fig. 2A ). Similar to previous studies (Goodrich et al. 1997) , heterozygous mutations in Ptch1 resulted in spontaneous medulloblastoma formation in 35% of animals, with a median latency of 179 days ( Fig. 2A ).
In these mice, the second copy of Ptch1 is mutated, with additional secondary mutations in other genes (Tamayo-Orrego et al. 2016) . Combining Bcor ΔE9-10 with Ptch1 mutations resulted in tumorigenesis with 100% penetrance and a median latency of 75 days ( Fig. 2A, p<0 .0001, Log-rank (Mantel-Cox) test). There was a histological switch from classic in Ptch1+/-tumors (N = 3/3, Fig. 2B) to the more aggressive histological subtype, large-cell anaplastic (LCA), in Ptch1+/-;Bcor ΔE9-10 tumors (N = 3/3, Fig. 2C ). To confirm that Ptch1+/-;Bcor ΔE9-10 tumor cells had higher tumorigenic potential, we transplanted 8x10 5 cells from either Ptch1+/-tumors or Ptch1+/-;Bcor ΔE9-10 tumors into the cerebella of immunodeficient mice. Ptch1+/-;Bcor ΔE9-10 tumor cells reestablished tumors considerably faster than Ptch1+/-tumor cells ( Fig. 2D , median latency 26 days compared to 150 days, p<0.0001,
To determine whether Bcor ΔE9-10 drives early transformation events, we next examined the number of preneoplastic lesions in the cerebella of P28 mice. Ptch1+/-animals carry a lacZ gene that disrupts one copy of the Ptch1 locus, and preneoplastic cell clusters, where the Ptch1 promoter is active, can be identified by betagalactosidase staining ( Fig. 2E ,F, Goodrich et al. 1997; Oliver et al. 2005) . We determined that Ptch1+/-;Bcor ΔE9-10 cerebella have twice the number of these regions compared to Ptch1+/-cerebella alone ( Table S1 ). Among the 448 significantly upregulated genes, we identified the growth factor Igf2 as upregulated ~20-fold in Ptch1+/-;Bcor ΔE9-10 tumors compared to Ptch1+/-tumors ( Fig. 3A , Log2FC: ~4.4, adj. p = 5.26e-30).
We also verified Igf2 overexpression using Affymetrix microarray data from an additional cohort of samples (Supplemental Fig. S2B ,C, Supplemental Table S2 ) and by performing qPCR on individual tumor samples ( Fig. 3B ).
Consistent with previous results ), we did not detect obvious Igf2 expression in P7 GNPs in wild-type animals ( Fig. 3B ). There was also no aberrant expression of Igf2 in P7 GNPs from either Ptch1+/-or Ptch1+/-; Bcor ΔE9-10 mice by qPCR ( Fig. 3B ) nor ISH ( Fig. 3C,D) . Additionally, we did not detect robust Igf2 expression in Ptch1+/-preneoplastic lesions or in Ptch1+/tumors ( Fig. 3B ,E,G). Instead, aberrant Igf2 expression was observed only in preneoplastic lesions of Ptch1+/-;Bcor ΔE9-10 animals ( Fig. 3F ) and in Ptch1+/-;Bcor ΔE9-10 tumors (Fig. 3B,H ), suggesting that inactivation of both alleles of Ptch1 is necessary for BCOR-dependent Igf2 regulation as well. We also confirmed that IGF2 protein is expressed in ICGC_MB204  ICGC_MB88  ICGC_MB62  ICGC_MB136  ICGC_MB250  ICGC_MB137  ICGC_MB275  ICGC_MB262  ICGC_MB60  ICGC_MB206  ICGC_MB179  ICGC_MB180  ICGC_MB101  ICGC_MB234  ICGC_MB61  ICGC_MB1  ICGC_MB34  ICGC_MB243  ICGC_MB178  ICGC_MB299  ICGC_MB181  ICGC_MB246  ICGC_MB56  ICGC_MB287  ICGC_MB194  ICGC_MB295  ICGC_MB68  ICGC_MB284  ICGC_MB132  ICGC_MB59  ICGC_MB266  ICGC_MB53  ICGC_MB193  ICGC_MB104  ICGC_MB21  ICGC_MB3  ICGC_MB268  ICGC_MB244  ICGC_MB102  ICGC_MB28  ICGC_MB239  ICGC_MB63  ICGC_MB274  ICGC_MB37  ICGC_MB12 RPKM IGF2 To determine whether Igf2 upregulation is a conserved mechanism across species, we examined human medulloblastoma samples in which both genomic and transcriptomic data are available (Table 1, Northcott et al. 2017) . Notably, we discovered that the only case of IGF2 overexpression was co-incident with a BCOR frameshift mutation (Fig. 3J ). The BCOR mutation in this sample was confirmed using RNA-seq alignment data, and BCOR is highly expressed in this sample compared to other SHHmedulloblastoma samples (Supplemental Fig. S2D ). While we also had one sample with a BCOR missense mutation (S1358Y) that did not exhibit upregulation of IGF2 (Fig. 3J ), this mutation is located within the pre-Ankyrin repeats and may not negatively affect BCOR function ( Fig. 1A ). BCOR expression in this tumor is also reduced compared to the rest of the cohort (Supplemental Fig. S2D ), and the mutation was detected in only 2% of the RNA-seq reads. Histologically, these tumors resembled Ptch1+/-;Bcor ΔE9-10 tumors and all displayed an anaplastic histology (Fig. 3O,   N=3 ).
Igf2 overexpression is sufficient to drive tumorigenesis in
Because Igf2 overexpression accelerated tumorigenesis in this model, we examined the level of Igf2 necessary for tumor induction and compared it to the expression level in the genetically engineered mouse models. We observed lower levels of Igf2 expression in the Igf2-IRES-eGFP induced tumors compared to Ptch1+/-;Bcor ΔE9-10 genetic tumors ( Fig. 3P ), suggesting the level of Igf2 in Ptch1+/-;Bcor ΔE9-10 tumors is more than sufficient to drive tumorigenesis. BCOR ΔE9-10 fails to interact with the PRC1.1 catalytic subunit RING1B, and the PUFD domain of BCOR is required for Igf2 repression
The C-terminal domain of BCOR mediates its interaction with the PRC1.1 complex, a multi-protein complex that transfers ubiquitin to H2AK119Ub via the E3 ubiquitin ligase RING1B to repress target gene transcription (Wang et al. 2004; . We tested whether the PRC1.1 complex is affected in Ptch1+/-;Bcor ΔE9-10 tumors. Similar to previous studies (Tara et al. 2018) , we found that BCOR ΔE9-10 no longer binds RING1B via co-immunoprecipitation in Ptch1+/-;Bcor ΔE9-10 tumor samples, while full-length BCOR and RING1B co-immunoprecipitate in Ptch1+/-tumor samples (Fig. 4A ).
In the genetically engineered mouse model, BCOR ΔE9-10 is missing both the PUFD domain, which is responsible Kutscher, Okonechnikov, Batora et al. ◄ cont. from Bcor ∆PUFD Bcor ∆E9-10 Bcor ∆E9-10 Bcor ∆E9-10 Bcor ∆E9-10 Igf2 TSS OFF which may interact with additional proteins outside of PRC1.1 (Fig. 1G) , and therefore may also mediate tumor suppression independent of PRC1.1. To verify that loss of the PUFD domain alone, rather than the entire C-terminus, is responsible for Igf2 activation during medulloblastoma formation, we conducted in utero electroporation (IUE) experiments to test the role of the PUFD domain specifically in tumorigenesis. We generated a single plasmid carrying tandem sgRNAs targeting Ptch1 (Zuckermann et al. 2015) and Bcor at exon 13 (107 nucleotides upstream of the PUFD domain coding sequence in the linker region, Supplemental   Table S3 ) and Cre recombinase. We injected this plasmid in the fourth ventricle of E13.5 embryos that carry a single copy transgene expressing a Rosa26::Lox-Stop-Lox-Cas9-IRES-GFP cassette (see Methods for details). In Ptch1;Bcor ΔPUFD IUE tumors, Igf2 is overexpressed compared to Ptch1 IUE control tumors ( Fig. 4B ), suggesting that loss of BCOR PUFD (Table S3 ), likely via disruption of PRC1.1 complex assembly and targeting (Wang et al. 2018) , aberrantly upregulates Igf2 transcription.
BCOR is bound at the Igf2 locus and represses gene transcription through H2AK119Ub
To determine whether BCOR is directly bound at the Igf2 locus, we conducted BCOR chromatin immunoprecipitation (ChIP) in Ptch1+/-and Ptch1+/-;Bcor ΔE9-10 tumor samples (see Methods for details). The BCOR antibody we used was raised against a region common to BCOR and BCOR ΔE9-10 (encoded within exons 6-8) and thus detects both forms in Western blot (Fig. 1H) and ChIP. Global levels of BCOR binding are reduced but not completely lost in Ptch1+/-;Bcor ΔE9-10 tumors compared to Ptch1+/-tumors (yellow panels, 2063/2093 peaks, Fig. 4C , Supplemental Table S4 ).
There is also a small set of genes with increased binding in the Ptch1+/-;Bcor ΔE9-10 samples (30/3093 peaks). Importantly, we also detect 3890 peaks that were unchanged between all the replicates of the two samples, suggesting that BCOR ΔE9-10 is indeed present. BCOR ΔE9-10 could be recruited by BCL6
to these loci but would be unable to interact with PRC1.1 components.
Next, we examined the Igf2 promoter region in Ptch1+/samples, and we found that indeed BCOR is associated with chromatin in that region (Fig. 4D ). We then checked the same region in Ptch1+/-;Bcor ΔE9-10 and discovered the BCOR peak is significantly reduced at the locus (Fig. 4D ,E, DiffBind, p-adj < 0.05). Given that BCOR ΔE9-10 no longer binds to the catalytic subunits of the PRC1.1 (Fig. 4A) , residual BCOR ΔE9-10 would only be capable of PRC1.1-independent functions.
If BCOR ΔE9-10 renders the PRC1.1 non-functional, then
H2AK119Ub levels should be reduced compared to Ptch1+/controls. To test this hypothesis, we performed H2AK119Ub
ChIP from chromatin prepared from the same tumor samples (see Methods for details). We found that total levels of H2AK119Ub decreased at peaks where BCOR signal is significantly decreased (red panels, Fig. 4C ), indicating that the enzymatic activity of PRC1.1 complex is indeed reduced at loci with less BCOR. At the Igf2 locus, H2AK119Ub levels are significantly reduced in Ptch1+/-;Bcor ΔE9-10 tumor samples ( Fig. 4D,F) . We also called differential Kutscher, Okonechnikov, Batora et al. ◄cont . from previous page Figure 4 . The PUFD domain of BCOR is required for Igf2 repression through H2AK119 Ubiquitination. (A) Co-immunoprecipitation of BCOR or BCOR ΔE9-10 with RING1B in Ptch1+/-and Ptch1+/-;Bcor ΔE9-10 tumor cells, respectively. IgG, Immunoglobulin G control. (B) Relative mRNA expression of Igf2 of two Ptch1 CRISPR tumors (gray), and two Ptch1;Bcor ΔPUFD CRISPR tumors (blue). (C) Heat map of significant differentially bound peaks from BCOR chromatin immunoprecipitation (ChIP) (yellow) between tumors from indicated genotypes and the status of H2AK119Ub ChIP signals (red) within these genomic loci. (D) Combined BCOR and H2AK119 ChIP peaks in indicated genotypes. Significantly different peak heights represented with yellow (BCOR) and red (H2AK119Ub) Table S3 , S4, Figure S3 .
H2AK119Ub peaks between the two tumor types and then examined BCOR binding status, observing a similar effect (Supplemental Fig. S3A ). In P7 cerebellum, BCL6 and BCOR are located at promoter regions of Gli1 and Gli2 (Tiberi et al. 2014) .
We examined these same regions in our samples, and we found decreased BCOR binding at these sites (Supplemental Fig. S3B,C) . However, H2AK119Ub levels are not significantly different at these regions, and there is no corresponding overexpression of Gli1 or Gli2 in Ptch1+/-; Bcor ΔE9-10 tumors (Supplemental Fig. S3B ,C Supplemental   Table S1 ,S2). These results suggest that that the recruitment of BCOR by BCL6 is not required to maintain repression of Gli1/Gli2. The maintenance of H2AK119Ub at these loci suggests that other PRC1 complexes may compensate to prevent Gli1/Gli2 overexpression.
Altogether, our results suggest that lack of fulllength BCOR in Ptch1+/-;Bcor ΔE9-10 tumors leads to direct upregulation of Igf2, and this aberrant Igf2 expression is closely associated with reduced H2AK119Ub and a disrupted PRC1.1 complex (Fig. 4G) , enhancing the incidence of malignant transformation during tumor progression.
DISCUSSION
BCOR functions as a tumor suppressor in SHHmedulloblastoma, independent of BCL6
BCOR is a large, multi-domain protein implicated as a tumor suppressor in many pediatric cancers (Astolfi et al. 2019 where a C-terminally truncated protein, retaining the BCL6 binding region but lacking the region for interaction with PRC1.1 components, is predicted to be produced.
Bcor ΔE9-10 must be at least a partial loss-of-function because we have removed the domain critical domain for PRC1.1 interaction, and we find the levels of the truncated protein are significantly reduced in GNPs. However, we cannot exclude the possibility that the residual protein retains activity, but this activity would have to be independent of PRC1.1. It has been proposed previously that BCOR, in conjunction with BCL6 and SIRT1, represses Gli1/Gl2 (Tiberi et al. 2014) . Although binding of BCOR to the Gli1/Gli2 loci is significantly reduced, Gli1/Gli2 mRNA expression is normal in the Bcor ΔE9-10 mutants, indicating that the residual activity is sufficient to repress Gli1/Gli2. Thus, our results show that the clinically relevant BCOR mutations modeled here act independently of the previously described BCL6/BCOR/SIRT1 regulation of Gli1/Gli2 (Tiberi et al. 2014 ). Furthermore, recurrent BCL6 mutations have yet to be identified in SHH-medulloblastoma patient samples, suggesting that BCOR and its PRC1.1-related functions may be more relevant to human tumor formation.
BCOR directly represses Igf2 via PRC1.1 complex-mediated H2AK119 ubiquitination
Our results suggest that BCOR directly regulates Igf2 transcription via interaction with other components of the PRC1.1 complex, which deposits H2AK119Ub repressive histone marks at the Igf2 promoter. While our ChIP studies were conducted in progressive mouse medulloblastomas, this mechanism likely occurs in preneoplastic lesions of Ptch1+/-animals as well (given Igf2 upregulation in Ptch1+/-;Bcor ΔE9-10 cerebellum). 85% of Ptch1+/-animals have preneoplastic lesions at P21, but only 15%-20% of animals develop progressive medulloblastoma Kessler et al. 2009 ), suggesting that BCOR-PRC1.1 may function in preneoplastic cells to prevent aberrant Igf2 overexpression. This hypothesis is further strengthened by the fact that IGF2 is necessary for late stage SHHmedulloblastoma progression (Hahn et al. 2000; Corcoran et al. 2008) . Nevertheless, no recurrent mutations of genes that encode components of PRC1.1 other than BCOR have been identified in SHH-medulloblastoma. Perhaps these mutations influence cell viability in the developing brain, potentially leading to cell death rather than tumorigenesis.
If Igf2 upregulation is indeed required to push tumor- Igf2 upregulation at P7. Presumably at P7, some single cells may have acquired mutations in Ptch1 in both alleles, but these single cells would be difficult to detect in ISH slices at P7. However, these single cells then form preneoplastic outgrowths, which lack Ptch1 and only express Bcor ΔE9-10 , and thus overexpress Igf2.
Of note, mutations in BCOR and other PRC1.1 complex components have been identified in other tumor types. For example, the PRC1.1 complex is also important in preventing T-cell acute lymphoblastic leukemia (T-ALL). Mice lacking the PUFD domain of BCOR (same floxed allele as present study) or the zinc finger domain of KDM2B both developed lethal T-ALL (Tara et al. 2018; Isshiki et al. 2019 ), suggesting a broader role for PRC1.1 as a tumor suppressor in cancer.
Notably, Bcor ΔE9-10 on its own was enough to induce T-ALL, suggesting a different mechanism is likely involved.
IGF2 overexpression may be a general feature of BCOR altered tumors
Internal tandem duplications in the C-terminus of BCOR in CNS-HGNET-BCOR tumors exhibit upregulation of IGF2 (Vewinger et al. 2019 ), suggesting that suppression of IGF2 expression may be a general feature of BCOR function across pediatric brain tumor entities. Importantly, CNS-HGNET-BCOR tumors exhibit aberrant activation of the SHH pathway (Paret et al. 2016 ), suggesting that both SHH pathway activation and BCOR aberrations cooperate to activate IGF2, similar to our Ptch1+/-;Bcor ΔE9-10 tumors. 
2017). Intriguingly, IGF2 overexpression is associated with
Ptch1-related rhabdomyosarcoma (Hahn et al. 2000) . It will be interesting to determine whether there is any link between BCOR alterations and IGF2 overexpression in sarcomas, especially in sarcomas with SHH pathway aberrations.
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Materials and Methods Animals
Bcor conditional knockout mice were generated by breeding of Bcor fl/fl (loxP sites flanking exons 9 and 10, Hamline et al. in prep.) with Atoh1-Cre (JAX, #011104) and Ptch1 heterozygous mice (Goodrich et al. 1997) . Genotyping primer sequences are available in Supplemental Table S5 . G-182/13, G-48/14, G-64/14, G-29/18, and G-23/19) .
in utero electroporation in utero electroporation was performed as previously described (Feng et al. 2017) . For these experiments, we used a single px330 plasmid (Addgene #42230) modified to carry two sgRNA cassettes, and Cre recombinase coding sequence was used in place of Cas9. This plasmid together with a luciferase encoding plasmid was injected into the fourth ventricle of E13.5 embryos and electroporated (30V, 50 mson, 950 ms-off, 5 pulses). Positive pups were identified by luciferase signal at P7 and animals were monitored daily for the first neurological signs of medulloblastoma formation.
Orthotopic transplantation
For retransplantation experiments, 8x10 5 freshly isolated, purified tumor cells from Ptch1+/-or Ptch1+/-;Bcor ΔE9-10 animals were retransplanted to the cerebellum of NSG mice, according to published SOP (Brabetz et al. 2018) , and animals were monitored daily for signs of tumor growth.
For Igf2 overexpression studies, retroviruses were freshly generated as previously described (Kawauchi et al. 2012 ). 1x10 6 P7 GNPs isolated from Ptch1+/-mice were cultured in vitro and transduced with MSCV-based retroviruses carrying Igf2-IRES-eGFP, Mycn-IRES-eGFP (positive control), or eGFP only (negative control). Two days later, GFP+ GNPs were harvested and transplanted to NSG mice in the same manner as above.
EdU injections and imaging
P7 mice of the appropriate genotype were injected intraperitoneally with 10 mg/ml stock solution of EdU (50 mg/kg, 20ul total volume, dissolved in PBS, Invitrogen).
Mice were sacrificed at P8 (proliferation) or P28 (migration).
EdU labeling reaction was conducted as described in (Zeng et al. 2010 (Zuckermann et al. 2018) . For Ptch1 only targeting construct, the sgRNA for Bcor was replaced with a control sgRNA (GCGACCAATACGCGAACGTC). For MSCVbased plasmids, the coding region for Igf2, Mycn, or empty vector was cloned using BamHI and XhoI sites. For co-IP plasmids, full-length Bcor cDNA or truncated Bcor ΔE9-10 cDNA was cloned with an N-terminal HA tag into pCAG vector using InFusion (Takara). pCMV-SPORT 6.1 with mouse Bcl6 cDNA was purchased from Horizon Discovery (Clone ID 6309948).
in situ hybridization in situ hybridization (ISH) was performed as described previously (Kawauchi et al. 2006) . Plasmids containing the coding region of Bcor (Clone ID 6412868, Horizon Discovery), Igf2 (Clone ID 30013295, Horizon Discovery), and Ccnd2 (5716186, Horizon Discovery) were linearized with XhoI, EcoRI, and AccI, respectively, and used to generate antisense RNA probes (DIG RNA labeling kit, Roche).
Probes were hybridized on 10μm-thick cryosections of the cerebellum or tumor samples of interest and counterstained with Methyl green (Sigma). For expression pattern analysis, we checked three independent cerebella and all ISH results reported in this paper were consistent in all three samples.
Histopathology and Immunostaining
For histopathology, samples of mouse medulloblastomas (3 tumors per genotype) were formalin-fixed, paraffinembedded and sectioned at 5 μm. The sections were stained with hematoxylin and eosin (H&E), and histological classifications were performed blinded to genotype.
Immunostaining was performed as previously described (Pajtler et al. 2019 (Kawauchi et al. 2012) . For in vitro studies, 5 million cells were plated per well in a 6-well plate and cultured for 48h in the presence or absence of 200 nM smoothened agonist (Merck). RNA was extracted and cDNA was generated with Superscript II kit (Invitrogen), according to manufacturer's instructions. RNA and cDNA from tumor samples was generated similarly. Relative gene expression was compared to Gapdh in all experiments except Fig. 3P and 4B , which was compared to the geometric mean of Hrpt1, Rpl27, and Rer1 (Thomas et al. 2014) . All primer sequences are listed in Supplemental Table S5 . 
Co-immunoprecipitation
Co-immunoprecipitation studies of BCOR and BCL6 were performed similar to (Huynh et al. 2000) . Briefly, we overexpressed cDNAs expressing HA-tagged full-length BCOR or BCOR ΔE9-10 with BCL6. We also included a BCL6only negative control. We used HEK293T cells for these experiments (CRL-3216). Three days after transfection, we harvested the cells and extracted protein in LB200 buffer (20 mM Tris, pH 8, 1% Triton-X, 1 mM EDTA, 1mM EGTA, sonication. After preclearing anti-HA beads (Pierce) with 1% BSA in PBS, 51 μg of total protein lysate were bound to the beads for 1h at 4 o C, rotating. After three wash steps with LB200 at 4 o C, we eluted the bound proteins with 2x SDS Laemmli buffer and ran total lysate on 4-12% bis-Tris gradient gel (NuPAGE, Thermo Fisher Scientific) for downstream Western blotting.
For interaction tests between RING1B and BCOR-FL / BCOR ΔE9-10 in mouse tumor samples, tumor cells were lysed in LB200 buffer with sonication. Anti-RING1B antibody was bound to IgG beads (#39663, Active Motif, 1:500) for 1h at RT before applying 500 μg of the total cell lysate.
Proteins were allowed to bind for 4h at RT, rotating. After three wash steps with LB200 at RT, bound proteins were eluted as above.
X-gal whole mount staining X-gal staining was performed as previously described (Zindy et al. 2014) . Brains were fixed in fresh 4% PFA / PBS for 1 hour on ice, rinsed in x-gal Rinse Buffer (100 mM sodium phosphate, pH 7.3, 2 mM MgCl 2 , 0.01% sodium deoxycholate, 0.02% (w/v) NP-40) 3x10min, followed by x-gal Staining Solution (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal (in DMF)) 37°C overnight. After, brains were placed in formalin (10%) and the number of preneoplastic lesions per cerebellum was quantified on a stereomicroscope (N=3 per genotype).
Human tumor data analysis
The presence of BCOR mutations and indels was integrated from the medulloblastoma landscape study (Northcott et al. 2017 ). For available samples, the IGF2 gene expression was checked from RNA-sequencing data (Fig. 3J) . Additionally, the BCOR somatic indel in sample MB12 was confirmed via RNA-seq alignment data. We only detected 2% of reads with the missense mutation in MB234, however.
Mouse model gene expression analysis RNA extraction
Tissue was homogenized using the Tissue Master 125 Homogenizer (OMNI International) and/or QIAshredder (Qiagen). RNA was extracted with RNeasy Mini Kit (Qiagen) following supplier's instructions. For measurement of RNA quantity, ND1000 Spectrophotometer (NanoDrop Technologies) and/or Agilent 2100 Bioanalyzer was used.
RNA sequencing libraries were processed and sequenced on a HiSeq V4 (SR 50) by the DKFZ Genomics Core Facility.
RNA-seq analysis
Initial transcriptome profiling was performed using RNAsequencing data from Ptch1+/-(N=3) and Ptch1+/-;Bcor ΔE9-10 (N=3) medulloblastoma tumor models. The alignment was performed using STAR v2.4.1 tool (Dobin et al. 2013 
